Liver Diseases and the Hemostasis (Rewiew) Part 1. Non-Cholestatic Diseases of the Liver and Hemostasis
https://doi.org/10.15360/1813-9779-2019-5-74-87
Abstract
In liver diseases, most commonly in the terminal stage of liver failure, a variety of hemostatic defects affecting almost all parts of the blood coagulation system are developing. This leads to diminishing the capabilities of patients with liver diseases to correctly maintain the hemostatic balance.
The severity of hemostatic disorders depends on the nosological form and degree of a liver damage. Depending on the imbalance of the hemostasis system and accumulated clinical/laboratory data, patients with liver diseases can be subdivided into three groups as exhibiting: 1. non-cholestatic liver damage; 2. cholestatic liver damage and 3. liver damage of vascular origin.
The first part of the review discusses multiple alterations in the hemostasis system in patients with noncholestatic liver diseases, which are commonly accompanied by hypocoagulation.
About the Authors
V. I. Reshetnyak
A. I. Evdokimov Moscow State University of medicine and dentistry, Ministry of Health of Russia
Russian Federation
20 Delegatskaya Str., Build 1, 127473 Moscow, Russia
Russian Federation
20 Delegatskaya Str., Build 1, 127473 Moscow, Russia
I. V. Maev
A. I. Evdokimov Moscow State University of medicine and dentistry, Ministry of Health of Russia
Russian Federation
20 Delegatskaya Str., Build 1, 127473 Moscow, Russia
Russian Federation
20 Delegatskaya Str., Build 1, 127473 Moscow, Russia
T. M. Reshetnyak
V. A. Nasonova Research Institute of Rheumatology
Russian Federation
34A Kashirskoye highway, Moscow 115522, Russia
Russian Federation
34A Kashirskoye highway, Moscow 115522, Russia
S. V. Zhuravel
N. V. Sklifosovsky Research Institute of Emergency Care, Moscow Healthcare Department
Russian Federation
3 Bolshaya Sukharevskaya Square, Moscow 129090, Russia
Russian Federation
3 Bolshaya Sukharevskaya Square, Moscow 129090, Russia
V. M. Pisarev
V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology
Russian Federation
25 Petrovka Str., Build. 2, 107031 Moscow, Russia
Russian Federation
25 Petrovka Str., Build. 2, 107031 Moscow, Russia
References
1. Batyrova A.S., Bakanov M.I., Surkov A.N. Up-to-date ideas about hemostasis system in chronic liver diseases (literature review). Klinicheskaya laboratornaya diagnostika. 2015; 60 (8): 40–44 [In Russ.]
2. Tischendorf M., Miesbach W., Chattah U., Chattah Z., Maier S., Welsch C., Zeuzem S., Lange C.M. Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical Implications. PLoS One. 2016; 11 (5): e0155337. DOI: 10.1371/journal.pone.0155337. PMID: 27171213
3. Intagliata N.M., Caldwell S.H. Changes in hemostasis in liver disease. J. Hepatol. 2017 Dec; 67 (6): 1332–1333. DOI: 10.1016/j.jhep.2017.07.001. PMID: 29156209.
4. Tripodi A. Hemostasis in Acute and Chronic Liver Disease. Semin Liver Dis. 2017; 37 (1): 28–32. DOI: 10.1055/s-0036-1597770. PMID: 28201846
5. Flores B., Trivedi H.D., Robson S.C., Bonder A. Hemostasis, bleeding and thrombosis in liver disease. J Transl Sci. 2017; 3 (3). DOI: 10.15761/JTS.1000182. PMID: 30221012
6. Minov A.F., Dzyadzko A.M., Rummo O.O. Prognostic meaning of indicators of hemostasis at liver diseases.Vestnik transplantalogii i iskusstvennyh organov. 2010; 2 (12): 82–91 [In Russ.]
7. Morozov Yu.A., Mednikov R.V., Charnaya M.A. Violations of the hemostatic system in liver pathology and their diagnosis. Gemorragicheskie diatezy, trombozy, trombofilii.2014; 1: 162–174 [In Russ.]
8. Sira J., Eyre L. Physiology of Hemostasis. Anaesthesia & Intensive Care Medicine. 2016; 17 (2): 79–82
9. Reshetnyak V.I., Zhuravel S.V., Kuznetsova N.K., Pisarev V.М., Klychnikova E.V., Syutkin V.Е., Reshetnyak Т.M. The System of Blood Coagulation in Normal and in Liver Transplantation (Review). Obschaya Reanimatologiya=General Reanimatology. 2018; 14 (5): 58–84. [In Russ.]. DOI: 10.15360/1813-9779-2018-5-58-84
10. Lisman T., Porte R.J. Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. Res Pract Thromb Haemost. 2017; 1 (2): 150–161. DOI: 10.1002/rth2.12028. PMID: 30046685
11. Batty P., Smith J.G. Hemostasis. Surgery. 2010; 28: 530–535. DOI: 10.1016/j.mpsur.2010.08.008
12. Schekotov A.P. Markers of endothelium damage and platelet aggregation in chronic hepatitis and liver cirrhosis. Klinizist. 2012; 1: 31–35 [In Russ.]
13. Palta S., Saroa R., Palta A. Overview of the coagulation system. Indian J. Anaesth. 2014; 58: 515e23
14. Demina I.A., Kumskova M.A., Panteleev M.A. Trombocitopatias. Rossijskij zhurnal detskoj gematologii i onkologii. 2015; 1: 54–60 [In Russ.]
15. Mirzaev K.B., Andreev D.A, Sychev D.A. Assessment of platelet aggregation in clinical practice. Racionainaya farmokoterapiya v kardiologii. 2015; 1(11): 85–91. [In Russ.]
16. Shitikova A.S. Platelet hemostasis. SPb; Ed. SPb GMU im. akad. I. P.Pavlova; 2000 [In Russ.]
17. Gao C., Xie R., Yu C., Ma R., Dong W., Meng H., Zhang Y., Si Y., Zhang Z., Novakovic V., Zhang Y., Kou J., Bi Y., Li B., Xie R., Gilbert G.E., Zhou J., Shi J. Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle Release. PLoS One. 2015; 10 (11): e0142835. DOI: 10.1371/journal.pone.0142835. PMID: 26580207
18. He Z., Zhang Y., Cao M., Ma R., Meng H., Yao Z., Zhao L., Liu Y., Wu X., Deng R., Dong Z., Bi Y., Kou J., Novakovic V., Shi J., Hao L. Increased phosphatidylserine-exposing microparticles and their originating cells are associated with the coagulation process in patients with IgA nephropathy. Nephrol Dial Transplant. 2016; 31 (5): 747–759. DOI: 10.1093/ndt/gfv403. PMID: 26673909
19. Zhao L., Wu X., Si Y., Yao Z., Dong Z., Novakovic V.A., Guo L., Tong D., Chen H., Bi Y., Kou J., Shi H., Tian Y., Hu S., Zhou J., Shi J. Increased blood cell phosphatidylserine exposure and circulating microparticles contribute to procoagulant activity after carotid artery stenting. J Neurosurg. 2017; 127 (5): 1041–1054. DOI: 10.3171/2016.8.JNS16996.PMID: 28009236
20. Shaw A.W., Pureza V.S., Sligar S.G., Morrissey J.H. The local phospholipid environment modulates the activation of blood clotting. J. Biol. Chem. 2007; 282: 6556–6563. DOI: 1074/jbc.M607973200. PMID: 17200119
21. Morrissey J.H., Pureza V., Davis-Harrison R.L., Sligar S.G., Ohkubo Y.Z., Tajkhorshid E. Blood clotting reactions on nanoscale phospholipid bilayers. Thromb Res 2008; 122 Suppl 1: S23–S26. DOI: 10.1016/S0049-3848 (08)70014-8. PMID: 18691494]
22. Smith S.A, Morrissey J.H. Polyphosphate: a new player in the field of hemostasis. Curr Opin Hematol 2014; 21: 388–394. DOI: 10.1097/MOH.0000000000000069. PMID: 25010799]
23. Tavoosi N., Davis-Harrison R.L., Pogorelov T.V., Ohkubo Y.Z., Arcario M.J., Clay M.C., Rienstra C.M., Tajkhorshid E., Morrissey J.H. Molecular determinants of phospholipid synergy in blood clotting. J Biol Chem 2011; 286: 23247–23253. DOI: 10.1074/jbc.M111.251769. PMID: 21561861
24. Boettcher J.M., Davis-Harrison R.L., Clay M.C., Nieuwkoop A.J., Ohkubo Y.Z., Tajkhorshid E., Morrissey J.H., Rienstra C.M. Atomic view of calcium-induced clustering of phosphatidylserine in mixed lipid bilayers. Biochemistry 2011; 50: 2264–2273. DOI: 10.1021/bi1013694.PMID: 21294564
25. Morrissey J.H., Tajkhorshid E., Sligar S.G., Rienstra C.M. Tissue factor/factor VIIa complex: role of the membrane surface. Thromb Res 2012; 129 Suppl 2: S8–S10. DOI: 10.1016/j.thromres.2012.02.019. PMID: 22417943
26. Tavoosi N., Smith S.A., Davis-Harrison R.L., Morrissey J.H. Factor VII and protein C are phosphatidic acid-binding proteins. Biochemistry2013; 52: 5545–5552. DOI: 10.1021/bi4006368. PMID: 23879866
27. Muller M.P., Wang Y., Morrissey J.H., Tajkhorshid E. Lipid specificity of the membrane binding domain of coagulation factor X. J. Thromb. Haemost. 2017; 15: 2005–2016. DOI: 10.1111/jth.13788.PMID: 28782177
28. Ke K., Yuan J., Morrissey J.H. Tissue factor residues that putatively interact with membrane phospholipids. PLoS One 2014; 9: e88675. DOI: 10.1371/journal.pone.0088675. PMID: 24516673
29. Senzolo M., Burra P., Cholongitas E., Burroughs A.K. New insights into the coagulopathy of liver disease and liver transplantation. World. J. Gastroenterol 2006; 12: 7725–7736. DOI: 10.3748/wjg.v12.i48.7725. PMID: 17203512
30. Vorobjov P.A. Diagnostics and treatment of violations of hemostasis. М.; Njudiamed; 2011 [In Russ.].
31. Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease. N. Engl J Med. 2011; 365 (2): 147–156. DOI: 10.1056/NEJMra1011170. PMID: 21751907
32. Tischendorf M., Miesbach W., Chattah U., Chattah Z., Maier S., Welsch C., Zeuzem S., Lange C.M. Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical Implications. PLoS One. 2016; 11 (5): e0155337. DOI: 10.1371/journal.pone.0155337. PMID: 27171213
33. Bilalova A.R., Makashova V. V., Astrina O. S., Aleshina N. I. Features of hemostasis system in patients with chronic hepatitis and liver cirrhosis. Infecionnie bolezni. 2015; 3 (13): 37–45 [In Russ.].
34. Tripodi A., Primignani M., Lemma L., Chantarangkul V., Mannucci P.M. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J. Hepatol 2013; 59: 265–270. DOI: 10.1016/j.jhep. 2013.03.036. PMID: 23583273
35. Lisman T., Bernal W. Management of Hemostatic Disorders in Patients With Advanced Liver Disease Admitted to an Intensive Care Unit. Transfus Med Rev. 2017 Oct; 31 (4): 245–251. DOI: 10.1016/j.tmrv.2017.06.002. PMID: 28734547
36. Witters P., Freson K., Verslype C., Peerlinck K., Hoylaerts M., Nevens F., Van Geet C., Cassiman D. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther. 2008; 27 (11): 1017–1029. DOI: 10.1111/j.1365-2036.2008.03674.x. PMID: 18331464
37. Afdhal N., McHutchison J., Brown R., Jacobson I., Manns M., Poordad F., Weksler B., Esteban R. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008; 48 (6): 1000–1007. DOI: 10.1016/j.jhep.2008.03.009. PMID: 18433919
38. Cheong J.Y. Anticoagulation in Patients with Liver Cirrhosis. KoreanJ Gastroenterol. 2017; 70 (5): 218–222. DOI: 10.4166/kjg.2017.70.5.218. PMID: 29161790
39. Leonardi F., Maria N., Villa E. Anticoagulation in cirrhosis: a new paradigm? Clin Mol Hepatol. 2017; 23 (1): 13–21. DOI: 10.3350/cmh.2016.0110. PMID: 28288507
40. Leebeek F.W., Rijken D.C. The Fibrinolytic Status in Liver Diseases. Semin Thromb Hemost. 2015; 41 (5): 474–480. DOI: 10.1055/s-0035-1550437. PMID: 26049070
41. Moan A.S. The evaluation of liver dysfunction: when to suspect portal hypertension. JAAPA. 2009; 22 (4): 38–42. PMID: 19452820, DOI: 10.1097/01720610-200904000-00010
42. Reshetnyak T.M., Seredavkina N.V., Satybaldyeva M.A., Nasonov E.L., Reshetnyak V.I. Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome. World J Hepatol 2015; 7: 2229–2236. DOI: 10.4254/wjh.v7.i19.2229. PMID: 26380049
43. Stroh G., Rosell T., Dong F., Forster J. Early liver transplantation for patients with acute alcoholic hepatitis: public views and the effects on organ donation. Am J Transplant 2015; 15: 1598–1604. DOI: 10.1111/ajt.13176. PMID: 25707427
44. Zanetto A., Ferrarese A., Bortoluzzi I., Burra P., Russo F.P. New perspectives on treatment of hepatitis B before and after liver transplantation. Ann Transplant 2016; 21: 632–643. DOI: 10.12659/AOT.900216. PMID: 27739420
45. Khungar V., Goldberg D.S. Liver transplantation for cholestatic liver diseases in adults. Clin Liver Dis 2016; 20: 191–203. DOI: 10.1016/j.cld.2015.08.011. PMID: 26593299
46. Ma K.W., Chok S., Chan C.K., Dai W.C., Sin S.L., Lau F.L., Chan S.C., Lo C.M. Liver transplantation: a life-saving procedure following amatoxin mushroom poisoning. Hong Kong Med J 2017; 23: 93–96. DOI: 10.12809/hkmj154616. PMID: 28184019]
47. Gunsar F. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Exp Clin Transplant 2017; 15 Suppl 2: 59–64. DOI: 10.6002/ect.TOND16.L16. PMID: 28302001
48. Biolato M., Araneo C., Marrone G., Liguori A., Miele L., Ponziani F.R., Gasbarrini A., Grieco A. Liver transplantation for drug-induced acute liver failure. Eur Rev Med Pharmacol Sci 2017; 21 1 Suppl: 37–45. PMID: 28379596
49. Marot A., Dubois M., Trépo E., Moreno C., Deltenre P. Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis. PLoS One 2018; 13: e0190823. DOI: 10.1371/journal.pone.0190823. PMID: 29324766
50. Shklyaev A.E., Malahova I.G. Prognostic value of hemostasis indicators in liver diseases. Tromboz, gemostaz i reologiya. 2016; 3 (67): 462–464 [In Russ.].
51. Gulyaeva I.L., Pestrenin L.D., Logunov A.V., Bulatova I.A. Haemostasis pathology and endothelial dysfunction in hepatitis B: current status of the issue.Tromboz, gemostaz i reologiya. 2017; 4 (72): 14–19 [In Russ.].
52. Galeeva N.V., Kravchenko I.E. Indicators of hemostasis in patients with chronic hepatitis C. Epidemiologiya i infekcionnye bolezni. 2018; 23 (6): 279–285 [In Russ.].
53. Chen J., Duan Z.P., Bai L., Zhao J., Ding M., Tong X.Y., Cong Y.L. Changing characteristic of blood coagulation factors and their correlation with blood coagulation status in different hepatic diseases. [Article in Chinese] Zhonghua Gan Zang Bing Za Zhi. 2012; 20 (3): 206–210. DOI: 10.3760/cma.j.issn.1007-3418.2012.03.014. PMID: 22475141
54. Kurkina I.A., Maevskaya M.V., Ivashkin V.T. Features of hemostasis in liver disfunction. Gastroenterologiya (special issue). 2015; 2: 7–10 [In Russ.].
55. Yagoda A.V., Koroj P.V. Liver pathology and platelet function (clinical and pathogenetic analysis).Stavropol: StGMA; 2008 [In Russ.].
56. Pradella P., Bonetto S., Turchetto S., Uxa L., Comar C., Zorat F., De Angelis V., Pozzato G. Platelet production and destruction in liver cirrhosis. J. Hepatol. 2011; 54 (5): 894–900. PMID: 21145808. DOI: 10.1016/j.jhep.2010.08.018
57. Hayashi H., Beppu T., Shirabe K., Maehara Y., Baba H. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol 2014; 20: 2595–2605. DOI: 10.3748/wjg.v20.i10.2595. PMID: 24627595
58. Aref S., Sleem T., El Menshawy N., Ebrahiem L., Abdella D., Fouda M., Samara N.A., Menessy A., Abdel-Ghaffar H., Bassam A., Abdel Wahaab M. Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection. Hematology 2009; 14: 277–281. DOI: 10.1179/102453309X439818. PMID: 19843383
59. Escolar G., Cases A., Viñas M., Pino M., Calls J., Cirera I., Ordinas A. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999; 84: 614–619. PMID: 10406903
60. Clavien P.A., Camargo C.A.Jr, Croxford R., Langer B., Levy G.A., Greig P.D. Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation. Ann Surg 1994; 220: 109–120. DOI: 10.1097/00000658-199408000-00002. PMID: 8053733
61. Hersch S.L., Kunelis T., Francis R.B. Jr. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 1987; 69: 1315–1319. PMID: 2436684
62. Thakrar S.V., Mallett S.V. Thrombocytopenia in cirrhosis: Impact of fibrinogen on bleeding risk. World J Hepatol 2017; 9 (6): 318–325. DOI: 10.4254/wjh.v9.i6.318. PMID: 28293381
63. Kerr R. New insights into haemostasis in liver failure. Blood Coagul Fibrinolysis 2003; 14 Suppl 1: S43–S45. DOI: 10.1097/00001721-200306001-00011. PMID: 14567536
64. Lisman T., Bongers T.N., Adelmeijer J., Janssen H.L., de Maat M.P., de Groot P.G., Leebeek F.W. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53–61. DOI: 10.1002/hep.21231. PMID: 16799972
65. Feys H.B., Canciani M.T., Peyvandi F., Deckmyn H., Vanhoorelbeke K., Mannucci P.M. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534–540. DOI: 10.1111/j.1365-2141.2007.06688.x. PMID: 17608762
66. Hoffman M. Coagulation in liver disease. Semin Thromb Hemost 2015; 41: 447–454. DOI: 10.1055/s-0035-1550435. PMID: 26049068
67. Spiridonova E. A., Shchukin V. V., Zharkov P. A., Ataullakhanov F. I., Zeynalov A. M., Balandina A. N., Karelin A. F., Shimshirt M. A., Shman zer V. A., Selivanov V. V., Ovsyannikov Yu. G. Perioperative hemostasis monitoring: objective and laboratory support. Vestnik intensivnoj terapii. 2016; 1: 37–46 [In Russ.]
68. Koroy P. V. The role of platelet activation in the pathogenesis of thrombocytopenia in chronic liver disease. Medical Bulletin of the North Caucasus. 2006; (3): 16–19 [In Russ.]
69. Crivellin C., De Martin E., Germani G., Gambato M., Senzolo M., Russo F.P., Vitale A., Zanus G., Cillo U., Burra P. Risk factors in liver retransplantation: a single-center experience. Transplant Proc. 2011; 43 (4): 1110–1113. DOI: 10.1016/j.transproceed.2011.01.141. PMID: 21620065
70. Yang A., Guo Z., Ren Q., Wu L., Ma Y., Hu A., Wang D., Ye H., Zhu X., Ju W., He X. Active immunization in patients transplanted for hepatitis B virus related liver diseases: a prospective study. PLoS One 2017; 12: e0188190. DOI: 10.1371/journal.pone.0188190. PMID: 29145470
71. Bielen R., Robaeys G., Schelfhout S., Monbaliu D., Van der Merwe S., Pirenne J., Nevens F. Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos (t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study. Transpl Int 2018; 31 (5): 503–509. DOI: 10.1111/tri.13112. PMID: 29359868
72. Chauhan R, Lingala S., Gadiparthi C., Lahiri N., Mohanty S.R., Wu J., Michalak T.I., Satapathy S.K. Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management. World J. Hepatol 2018; 10 (3): 352–370. DOI: 10.4254/wjh.v10.i3.352. PMID: 29599899
73. Tao T., Jiang X., Chen Y., Song Y. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: a meta-analysis. Int J Infect Dis 2017; 55: 56–71. DOI: 10.1016/j.ijid.2016.12.023. PMID: 28040553
74. Globke B., Raschzok N., Teegen E.M., Pratschke J., Schott E., Eurich D. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: the role of ribavirin. Transpl. Infect. Dis. 2017; 19. DOI: 10.1111/tid.12647. PMID: 27943544
75. Rupp C., Hippchen T., Neuberger M., Sauer P., Pfeiffenberger J., Stremmel W., Gotthardt D.N., Mehrabi A., Weiss K.H. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World J Gastroenterol 2018; 24 (12): 1353–1360. DOI: 10.3748/wjg.v24.i12.1353. PMID: 29599610
76. Gadiparthi C., Cholankeril G., Perumpail B.J., Yoo E.R., Satapathy S.K., Nair S., Ahmed A. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J. Gastroenterol. 2018; 24 (3): 315–322. DOI: 10.3748/wjg.v24.i3.315. PMID: 29391754
77. Onishi Y., Kimura H., Hori T., Kishi S., Kamei H., Kurata N., Tsuboi C., Yamaguchi N., Takahashi M., Sunada S., Hirano M., Fujishiro H., Okada T., Ishigami M., Goto H., Ozaki N., Ogura Y. Risk of alcohol use relapse after liver transplantation for alcoholic liver disease. World J. Gastroenterol 2017; 23 (5): 869–875. DOI: 10.3748/wjg.v23.i5.869. PMID: 28223731
78. Kling C.E., Perkins J.D., Carithers R.L., Donovan D.M., Sibulesky L. Recent trends in liver transplantation for alcoholic liver disease in the United States. World J. Hepatol. 2017; 9 (36): 1315–1321. DOI: 10.4254/wjh.v9.i36.1315. PMID: 29359014
79. Kerr R., Newsome P., Germain L., Thomson E., Dawson P., Stirling D., Ludlam C.A. Effects of acute liver injury on blood coagulation. J. Thromb. Haemost 2003; 1: 754–759. DOI: 10.1046/j.1538-7836.2003.00194.x. PMID: 12871412
80. Hugenholtz G.C., Adelmeijer J., Meijers J.C., Porte R.J., Stravitz R.T., Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology 2013; 58: 752–761. DOI: 10.1002/hep.26372. PMID: 23468040
81. Pernambuco J.R., Langley P.G., Hughes R.D., Izumi S., Williams R. Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology 1993; 18: 1350–1356. DOI: 10.1002/hep.1840180611. PMID: 8244260
82. Bismuth H., Samuel D., Castaing D., Adam R., Saliba F., Johann M., Azoulay D.., Ducot B., Chiche L. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg. 1995; 222: 109–119. DOI: 10.1097/00000658-199508000-00002. PMID: 7639578
83. Khoroshilov S.E., Nikulin A.V. Detoxication in Critical Conditions: an Insight into the Scientific Problem in the XXI Century (Review).Obschaya reanimatologiya= General Reanimatology. 2017; 13 (5): 85–108. [In Russ.]. DOI: 10.15360/1813-9779-2017-5-85-108
84. Lisman T., Caldwell S.H., Burroughs A.K., Northup P.G., Senzolo M., Stravitz R.T., Tripodi A., Trotter J.F., Valla D.C., Porte R.J. Coagulation in Liver Disease Study Group. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J. Hepatol. 2010; 53: 362–371.
85. DOI: 10.1016/j.jhep.2010.01.042. PMID: 20546962
86. Lisman T., Porte R.J. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116: 878–885. DOI: 10.1182/blood-2010-02-261891. PMID: 20400681
Review
For citations:
Reshetnyak V.I., Maev I.V., Reshetnyak T.M., Zhuravel S.V., Pisarev V.M. Liver Diseases and the Hemostasis (Rewiew) Part 1. Non-Cholestatic Diseases of the Liver and Hemostasis. General Reanimatology. 2019;15(5):74-87. https://doi.org/10.15360/1813-9779-2019-5-74-87
Views:
3411
Email this article 